80 related articles for article (PubMed ID: 19760551)
1. [Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
Kasper B; Schmitt T; Wuchter P; Ho AD; Egerer G
Dtsch Med Wochenschr; 2009 Sep; 134(39):1922-6. PubMed ID: 19760551
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.
Kasper B; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Haberkorn U; Ho AD; Egerer G
Onkologie; 2008 Mar; 31(3):107-12. PubMed ID: 18322413
[TBL] [Abstract][Full Text] [Related]
3. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
Kasper B; Schmitt T; Wuchter P; Dimitrakopoulou-Strauss A; Ho AD; Egerer G
Mar Drugs; 2009 Jul; 7(3):331-40. PubMed ID: 19841717
[TBL] [Abstract][Full Text] [Related]
4. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Mechtersheimer G; Schmitt T; Lehner B; Haberkorn U; Stroebel P; Kasper B
J Nucl Med; 2010 Apr; 51(4):551-8. PubMed ID: 20351350
[TBL] [Abstract][Full Text] [Related]
5. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
Dimitrakopoulou-Strauss A; Strauss LG; Egerer G; Vasamiliette J; Schmitt T; Haberkorn U; Kasper B
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1481-9. PubMed ID: 20336454
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
8. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
11. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
12. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
Eary JF; Conrad EU; O'Sullivan J; Hawkins DS; Schuetze SM; O'Sullivan F
J Bone Joint Surg Am; 2014 Jan; 96(2):152-8. PubMed ID: 24430415
[TBL] [Abstract][Full Text] [Related]
13. Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.
Issels RD; Bosse D; Abdel-Rahman S; Starck M; Panzer M; Jauch KW; Stiegler H; Berger H; Sauer H; Peter K
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S233-7. PubMed ID: 8453705
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Elashoff D; Chow K; Evilevitch V; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
Clin Cancer Res; 2009 Apr; 15(8):2856-63. PubMed ID: 19351756
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide combination regimens for soft-tissue sarcoma.
Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Schütte J; Kellner R; Seeber S
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
20. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]